Jump to content

3,4-Methylenedioxy-N-methoxyamphetamine

From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by InternetArchiveBot (talk | contribs) at 20:53, 10 March 2024 (Rescuing 1 sources and tagging 0 as dead.) #IABot (v2.0.9.5) (Maxim Masiutin - 17955). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
3,4-Methylenedioxy-N-methoxyamphetamine
Names
Preferred IUPAC name
1-(2H-1,3-Benzodioxol-5-yl)-N-methoxypropan-2-amine
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C11H15NO3/c1-8(12-13-2)5-9-3-4-10-11(6-9)15-7-14-10/h3-4,6,8,12H,5,7H2,1-2H3 checkY
    Key: MTIKJUJMCMDSGM-UHFFFAOYSA-N checkY
  • InChI=1/C11H15NO3/c1-8(12-13-2)5-9-3-4-10-11(6-9)15-7-14-10/h3-4,6,8,12H,5,7H2,1-2H3
    Key: MTIKJUJMCMDSGM-UHFFFAOYAV
  • CC(NOC)Cc1ccc2OCOc2c1
Properties
C11H15NO3
Molar mass 209.245 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

3,4-Methylenedioxy-N-methoxyamphetamine (MDMEO, MDMEOA, or MDMeOA) is a lesser-known psychedelic drug and a substituted amphetamine. It is also the N-methoxy analogue of MDA. MDMEO was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 180 mg. MDMEO may be found as white crystals. It produces few to no effects. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDMEO.

Legality

[edit]

United Kingdom

[edit]

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[1]

See also

[edit]

References

[edit]
  1. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.
[edit]